N/A N=37 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2
Critical Illness · Oncology · Communication
Primary: Change in Prognostic Understanding — 0.58; 0.18 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants
Phase 2 N=216 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants
N/A N=57 Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer
Neoplasms
Primary: Mean Changes From Baseline in Self-esteem Scores on the Rosenberg Self-esteem Scale (RSES) to Two-, Six-, and Eight Weeks Post Baseline — 23.4; 23.5; 23.7; 24.2 score on…
N/A N=13 Managing Distress in Malignant Brain Cancer
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
Phase 1 N=84 A Study in Advanced Cancer
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 1 N=66 Marijuana in Combination With Opioids in Palliative and Hospice Patients
Pain
Primary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
N/A N=12 Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Cervical · Ovarian · Lung
Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention
N/A N=23 App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
Cancer
Primary: Interviews — 20 Interviews
Phase 1 N=34 Cancer Vaccine Targeting Brachyury Protein in Tumors
Neoplasms · Malignant Solid Tumors · Colon Neoplasms
Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants
Phase 2 N=48 Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
Lung Neoplasms · Ovarian Neoplasms · Cervix Neoplasms
Primary: Geometric Mean of Maximum Concentration of the Drug (Cmax) — 1315; 1093; 1060; 1026 Cmax (ng/mL)
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=58 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
N/A N=14 Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
Cutaneous Melanoma
Primary: Response Rate (RECIST1.1) of Calcium Electroporation and Bleomycin Based Electrochemotherapy on Cutaneous Metastases at Day 180. — 4; 6; 2; 2 cutaneous metastases — p=0.30
Phase 2 N=15 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
Phase 2 N=12 TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
Breast Cancer
Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…
Phase 1 N=31 Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
Intraabdominal Cancers (Various Types)
Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)